Toward a new model to accelerate innovation

- Claude Bertrand, Executive Vice President Research & Development

Our R&D model is constantly evolving to accelerate the delivery of medicines that respond to the real needs of patients. The establishment of the future Servier Paris-Saclay Research Institute is a perfect illustration of our desire to pursue more open, agile, and productive research to serve patients. This new R&D model is based on three pillars: focusing on projects with high added-value for patients, building on science and translational medicines and capitalising on the benefits of digital technology.

Servier organises its R&D in 3 therapeutic areas where it has extensive know-how and recognised expertise and in which there are important unmet needs: oncology, cardiometabolism and neurology/immuno-inflammation. Servier draws on the excellence of its 2900 R&D employees worldwide to develop effective treatment solutions.